A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy

Lisa Kottschade, Adam Brys, Tobias D Peikert, Mabel Ryder, Laura E. H. Raffals, Jerry Brewer, Paul Mosca, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

  • 11 Citations

Abstract

Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host's immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.

LanguageEnglish (US)
Pages469-480
Number of pages12
JournalMelanoma Research
Volume26
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Immunotherapy
Nervous System
Early Diagnosis
Pancreas
Cause of Death
Hospitalization
Homeostasis
Bone Marrow
Steroids
Morbidity
Kidney
Drug Therapy
Lung
Liver
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • immune-related adverse events
  • immunotherapy
  • metastatic melanoma

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. / Kottschade, Lisa; Brys, Adam; Peikert, Tobias D; Ryder, Mabel; Raffals, Laura E. H.; Brewer, Jerry; Mosca, Paul; Markovic, Svetomir Nenad.

In: Melanoma Research, Vol. 26, No. 5, 2016, p. 469-480.

Research output: Contribution to journalArticle

@article{d2e4e45f15b24245b7f5d0fe014a8178,
title = "A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy",
abstract = "Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host's immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.",
keywords = "immune-related adverse events, immunotherapy, metastatic melanoma",
author = "Lisa Kottschade and Adam Brys and Peikert, {Tobias D} and Mabel Ryder and Raffals, {Laura E. H.} and Jerry Brewer and Paul Mosca and Markovic, {Svetomir Nenad}",
year = "2016",
doi = "10.1097/CMR.0000000000000273",
language = "English (US)",
volume = "26",
pages = "469--480",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy

AU - Kottschade, Lisa

AU - Brys, Adam

AU - Peikert, Tobias D

AU - Ryder, Mabel

AU - Raffals, Laura E. H.

AU - Brewer, Jerry

AU - Mosca, Paul

AU - Markovic, Svetomir Nenad

PY - 2016

Y1 - 2016

N2 - Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host's immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.

AB - Immune-related Adverse Events (irAEs) are the most significant toxicities associated with the use of checkpoint inhibitors, and result from disinhibition of the host's immune homeostasis. The adverse effects experienced from immunotherapy are significantly different from those of chemotherapy and, to a lesser extent, targeted therapy. Early recognition and diagnosis of these toxicities is often challenging, but is critically important because of the potentially life-threatening nature and associated morbidity. Gastrointestinal, dermatologic, endocrine, and liver toxicities are the most commonly observed. Less commonly, the eyes, pancreas, kidneys, lungs, bone marrow, or nervous system may be affected. Although most irAEs may resolve with supportive care or discontinuation of drug, in severe cases, they may require hospitalization and immune suppressants, such as steroids, and/or may even cause death. The management of immune-related side effects requires a multidisciplinary approach.

KW - immune-related adverse events

KW - immunotherapy

KW - metastatic melanoma

UR - http://www.scopus.com/inward/record.url?scp=84974853773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974853773&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000273

DO - 10.1097/CMR.0000000000000273

M3 - Article

VL - 26

SP - 469

EP - 480

JO - Melanoma Research

T2 - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 5

ER -